A randomised trial of chlorambucil versus fludarabine as initial therapy of Waldenstrom's macroglobulinaemia and splenic lymphoma with villous lymphocytes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN56052618

Enrollment

400

Registered

2004-03-24

Start date

2006-06-01

Completion date

Unknown

Last updated

2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Waldenstrom's macroglobulinaemia and related disorders Cancer Malignant immunoproliferative diseases

Interventions

Current interventions as of 20/05/2008: This is a multicentre study. Patients are stratified according to disease (Waldenström macroglobulinemia versus splenic lymphoma with villous lymphocytes vs non

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with previously untreated disease who require therapy as judged by their primary physician and who satisfy the eligibilty criteria.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Added as of 20/05/2008: 1. Response to therapy (complete and partial response rates) 2. Duration of response	—

Secondary

Measure	Time frame
Added as of 20/05/2008: 1. Improvement in haematological parameters 2. Toxicity 3. Quality of life as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life-30 questionnaire 4. Survival	—

Countries

Australia, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026